Serum titers of antibody to Epstein-Barr virus (EBV) viral capsid antigen (VCA) have been positively correlated with malignancies of lymphoid proliferation, such as Burkitt's lymphoma and Hodgkin's lymphoma. We have constructed a phage display combinatorial antibody Fab library from a patient with marginal zone B cell lymphoma associated with Sjö gren's syndrome and carrying high serum anti-EBV-VCA IgG titer. Fab fragments were selected by panning against EBV-VCA protein coated onto ELISA plates, and selected Fab clones were characterized by ELISA, western blotting (WB), indirect immunofluorescence assay and immunohistochemistry. We have established two Fab clones, Fab-aVCA1 and Fab-aVCA21, which specifically recognize EBV-VCA by ELISA and WB. Inhibition ELISA competition showed that both clones could significantly reduce the binding of specific anti-EBV-VCA mAb to its relevant proteins. Furthermore, these two Fab clones could localize VCA protein in the EBV-positive P3HR1 and Daudi cell lines, as well as in tissue samples from patients with EBV-infected lymphoid malignancies. These results indicate that our two Fab clones are novel human mAbs specific for EBV-VCA protein and may have potential benefits for development of novel diagnostic and therapeutic approaches in EBV-related lymphoid malignancies.
Introduction
Epstein-Barr virus (EBV) is the first virus to be directly implicated in carcinogenesis in humans. EBV infects >90% of the world's adult population, and primary infection in a young adult can lead to infectious mononucleosis. Although most humans co-exist with the virus without serious sequels, this virus is strongly associated with several malignancies, including Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC) and Hodgkin's lymphoma (HL) (1, 2) . In cancer cells, EBV is present in a latent state, in which a subset of EBV genes is expressed, or in lytic cycles, which are characterized by the production of viral particles. Because viral capsid antigen (VCA) and early antigen, like the recently described EBV transactivator protein (ZEBRA), are expressed during EBV replication, cells expressing those EBV genes are more readily recognized by the immune system (3, 4) . Therefore, high anti-VCA IgG titers are considered to be a marker of EBV reactivity (5) . Remarkably, anti-VCA antibody titer is considerably higher in the sera of patients with BL, HL and NPC patients than in age-matched controls (1, 2) . Although the presence of serum anti-VCA IgG has been widely used for the diagnosis of EBV infection, the molecular profiles of this human antibody remain unknown. In addition, EBV was recently found to be associated with autoimmune diseases, such as systemic lupus erythematosus (6, 7) . Thus, the generation of EBV-VCA-specific human mAbs from human combinatorial Fab libraries could be of assistance in studies of molecular profiles of these antibodies and in the diagnosis of EBV infection at various stages.
The preparation of combinatorial libraries on the filamentous phage surface has been demonstrated to be an efficient route for the production of high affinity human mAbs (8, 9) . Their advantages over mouse mAb include the ability to alter antibody fragments by protein engineering methods. Thus, there have been many studies of recombinant Fab selected by target antigens, including viruses such as HIV types 1 and 2, human rotavirus and SARS by phage display (10) (11) (12) .
We have constructed a human antibody library from a patient carrying a high titer of serum anti-EBV-VCA IgG and successfully established two Fab clones by panning the Fab library against EBV-VCA. These two Fab fragments were found to bind to EBV-VCA with high affinity and were suitable for detecting EBV-VCA in EBV-infected malignant cells.
Methods

Library construction and phage display
After obtaining informed consent, we isolated 10 million bone marrow lymphocytes from a patient with Sjö gren's syndrome and marginal zone B cell lymphoma carrying a high titer of EBV-VCA IgG. Total RNA was isolated and used to generate cDNA, which was used as a template for PCR amplification of sequences in the region of Vh-Ch1 of the heavy chain and light chain j/k (13) . An antibody Fab library was constructed by the pComb3 M13 surface display system (13, 14) .
Panning selection of EBV-VCA antigen binding phage
Human Fab antibodies were selected by panning against commercially obtained EBV-VCA (Biogenesis Company, UK) as described (13) . A total of four cycles of panning were performed on 96-well ELISA plates pre-coated with 5 lg per well of EBV-VCA. Unbound phages were removed by washing 10 times with PBS/0.05% Tween 20. Bound human Fabs were detected with alkaline phosphatase (AP)-labeled goat anti-human IgG F(ab ) 2 (Pierce, Rockford, IL, USA), and visualized with p-Nitrophenyl phosphate disodium salt (pNPP) substrate (Pierce) by reading the absorbance at 405 nm.
DNA sequencing
DNA was amplified using a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, CA, USA). The primers for the variable region of the heavy (V H ) chain were T3 (5#-GAAGTAGTCCTTGACCAG-3# forward) and Gz (5#-GAA-GTAGTCCTTGACCAG-3#, reverse), and the primers for the variable region of the light (V L ) chain were KEF (5#-GAA-TTCTAAACTAGCTAGTCG-3#, forward) and Kb (5#-ATAGA-AGTTGTTCAGCAGGCA-3#, reverse). The products were sequenced on the ABI PRISM 310 Genetic Analyzer (Applied Biosystems).
Purification of Fab fragments
Monoclonal Fabs were purified by immunoaffinity chromatography, using polyclonal Goat anti-human IgG F(ab#) 2 (Pierce) conjugated to Gammabind G Sepharose (Amersham Bioscience, Piscataway, NJ, USA). After cross-linking with dimethyl pimelimidate (Pierce), Fab was purified (15) and its concentration was determined using the Bio-Rad protein microassay (CA, USA), and antibody purity was assessed by 12% SDS-PAGE followed by Quick-CBB staining (Wako, Osaka, Japan).
ELISA and inhibition analysis
To determine the reactivity of Fabs to EBV-VCA, 96-well microtiter plates were coated with 5 lg ml À1 EBV-VCA protein. After blocking with 3% BSA in PBS, the plates were washed with PBS/0.05% Tween 20 and incubated with twofold serial dilutions of purified Fab (0.625-10 lg per well in PBS), followed by 1:2500 diluted AP-conjugated goat antihuman IgG F(ab#) 2 and pNPP. The unrelated proteins, ovalbumin peptide (OVA) and human IgG Fc fragments, were used as control antigens to test non-specific binding (data not shown), and human recombinant Fab N28 anti-rotavirus was used as negative control (14) .
To determine the ability of our Fab clones to competitively inhibit the binding of mouse mAb to EBV-VCA, we performed inhibition ELISA. After determining the dilution of mouse mAb (Argene, clone F3.23, France) that bound 90% of EBV-VCA protein in mouse mAb capture ELISA (1:100; data not shown), microtiter plates were coated with 5 lg per well of EBV-VCA, and 50 ll per well of serially diluted Fabs in PBS and 50 ll per well of diluted mouse mAb (1:50) were added. The plates were incubated for 1.5 h at room temperature (RT), washed, and incubated with HRP-conjugated goat anti-mouse IgG (ICN Pharmaceutical Inc., CA, USA) (1:2000) and 1-Step TM ABTS [2-2#-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt] (Pierce) substrates, then the absorbance at 405 nm was determined.
Western blotting analysis
One-half microgram aliquots of EBV-VCA protein loaded onto each lane were separated by 10% SDS-PAGE, followed by electrophoresis and transfer to a nitrocellulose membrane (Bio-Rad) by the semi-dry system (Bio-Rad). After blocking with 3% skimmed milk, the membrane was incubated overnight at 4°C with purified Fab fragment (1ug ml À1 ). The membrane was subsequently incubated with HRP-labeled anti-human IgG F(ab#) 2 (Pierce) for 1 h at RT and the reaction was developed and visualized with ECL-plus (Amersham Life Science, UK) (16).
Indirect immunofluorescence assay
Recombinant Fabs (10 lg ml À1 ) were detected by indirect immunofluorescence assay (IFA) with FITC-conjugated goat anti-human IgG F(ab#) 2 antibody (Jackson Immunoresearch, PA, USA). EBV-infected P3HR1 and Daudi cells [American Type Culture Collection (ATCC), VA, USA] were fixed with acetone after cytospin on glass slides, with EBV-negative Jurkat cells (ATCC) used as control. 4#-6-Diamidino-2-phenylindole (DAPI) (Wako) was used to counterstain the nucleus. Mouse mAb was used as positive reference control and detected using PE-conjugated rabbit anti-mouse IgG antibody (Jackson Immunoresearch) (17) .
Immunohistochemistry and in situ hybridization
Paraffin-embedded tumor tissue samples from five patients with EBV-positive lymphoid malignancies were used for immunohistochemical identification of EBV-VCA by our Fab clones and mouse mAb. They were one BL patient, two HL (mixed cellularity) patients and two diffuse large B cell lymphoma patients. As control, we used spleen samples from a patient with EBV-negative BL. Deparaffinized slides were treated for 10 min with 3% H 2 O 2 to block endogenous peroxidase and 30 min with 3% skimmed milk. After antigen retrieval by autoclave heating, the slides were incubated for 1 h at RT with 10 lg ml À1 Fabs or 1:50 diluted mouse mAb. As control, slides were incubated with an anti-rotavirus Fab. After extensive washing with PBS, the slides were incubated for 1 h at RT with HRP anti-human IgG F(ab) 2 for Fabs and second antibody (Envision + Dual link system peroxidase, DAKO, Denmark) for mouse mAb. The slides were stained with DAB substrate (Envision DAB kit, DAKO) and counterstained with hematoxylin (DAKO). In situ hybridization (ISH) for EBV-encoded small RNA1 was performed simultaneously as described (18, 19) .
Results
Selection of Fab fragments
After four rounds of panning, two Fab clones (Fab-aVCA1 and Fab-aVCA21) were considered positive for EBV-VCA. The reactivity of these Fab clones against the relevant antigen was higher than 1.0 optical density (OD), whereas their reactivity against human IgG Fc fragment and OVA were <0.3 OD by ELISA. Both purified Fab fragments appeared as clear bands of molecular weight 28 kDa on SDS-PAGE (Fig. 1) .
Western blotting analysis of recombinant Fabs targeting EBV-VCA protein
Western blotting (WB) against EBV-VCA proteins was performed to define the targets of the recombinant monoclonal antibodies. Fab-aVCA1 recognized bands, of molecular weight 160, 85, 58 and 30 kDa (Fig. 2, lane 3) , whereas Fab-aVCA21 detected bands of 85, 58 and 30 kDa (Fig. 2,  lane 4) . To determine why the Fab fragments recognized multiple bands, the EBV-VCA proteins were blotted with mouse mAb, which recognized EBV-VCA proteins of molecular weight 160, 85, 58, and 30 kDa (Fig. 2, lane 2) , suggesting that the VCA protein may be proteolytically degraded (20) .
Amino acid sequences of Fab H and L chains
The amino acid sequences of the V H and V L chains of both Fab clones were deduced from DNA sequencing and compared with the closest known germ line proteins (Fig. 3) . The V H chain sequence of Fab-aVCA1 was derived from the V H 4 family whereas the V H chain sequence of Fab-aVCA21 was from the V H 3 family. The two Fab clones were found to share the same j light chain. Homologies to the closest germ line gene were 94% for both V L chains and 95 and 93% for the V H chains of Fab-aVCA1 and Fab-aVCA21, respectively. The nucleotide sequence data of our Fabs reported in this paper have been submitted to the DDBJ database and were assigned the following accession number: AB266511 (FabaVCA1 light chain), AB266512 (Fab-aVCA1 heavy chain) and AB266513 (Fab-aVCA21 heavy chain). and Fab-aVCA21. EBV-VCA protein (0.5 lg) was separated by 10% SDS-PAGE, and transferred to a nitrocellulose membrane. After blocking, the membrane was incubated overnight at 4°C with purified Fab fragment (1 lg ml 
ELISA and inhibition ELISA
Binding of Fab-aVCA1 and Fab-aVCA21 to EBV-VCA was examined using ELISA. Both Fab fragments showed high affinity, concentration-dependent binding to EBV-VCA, whereas the negative control, Fab anti-rotavirus, did not bind to EBV-VCA (Fig. 4A) . To further characterize the affinity of FabaVCA1 and Fab-aVCA21 to EBV-VCA, we compared their binding ability with that of mouse mAb (clone F3.23), which is specific for EBV-VCA, using inhibition ELISA. We found that Fab-aVCA21 significantly reduced the binding of mouse mAb to EBV-VCA, whereas Fab-aVCA1 showed a similar, but relatively weak effect, on binding (Fig. 4B) .
Specificity of Fab fragments by IFA, immunohistochemistry and ISH
To further investigate the interaction of the purified Fab fragments and EBV-VCA, we assayed the binding of purified Fab fragments to the EBV-positive P3HR1 and Daudi cell lines and the EBV-negative Jurkat cell line by IFA. Confocal microscopy showed that both Fab-aVCA1 and Fab-aVCA21 stained P3HR1 and Daudi (Fig. 5 ), but not Jurkat cells (data not shown). In contrast, no staining was observed using Fab anti-rotavirus (Fig. 5) . Immunohistochemically, we found that Fab-aVCA1 and Fab-aVCA21 specifically recognized EBV-VCA protein in EBV-infected lymphoma cells with good concordance with mouse mAb in five patients with EBV-positive lymphoid malignancies. Figure 6 showed staining of paraffin-embedded lymph node tissues from a patient with EBVpositive diffuse large B cell lymphoma by Fab-aVCA1 and Fab-aVCA21 (Fig. 6 B and C) . Staining with Fab anti-rotavirus (Fig. 6 D) and staining of control tissues (spleen from a patient with EBV-negative BL) were negative (Fig. 6 G-I) . These findings were confirmed by ISH (Fig. 6 E and J) .
Discussion
VCA is a complex of incompletely defined EBV late gene products associated with virion particles (21, 22) and expressed in the late period of EBV replication (17, 20) . The presence of EBV-VCA in EB-related malignant cells may be associated with EBV reactivation, which usually entails virus replication and excretion. It is likely that the exposure of EBV-infected cancer cells to the immune system leads to an increase in titer of anti-VCA antibodies. In this regard, anti-VCA IgG titers have been reported to be associated with EB viral load in patients with HL, patients infected with HIV and children receiving solid-organ transplants (23) (24) (25) . In addition, the presence of EBV-positive tumor cells has been associated with poorer survival in older patients with HL (26, 27) and advanced NPC (28) . Therefore, new effective implications for diagnosis of EBV infection and potentially clinical marker to monitor the presence of EBV-related lymphoid malignancies are required.
Phage display is a rapid and convenient way to isolate recombinant mAbs specific for various antigens (8) , including the isolation of a human monoclonal Fab fragment specific for EBV envelope glycoprotein, the gp350/220 antigen (29) . We have successfully identified two EBV-specific Fab fragments by panning a Fab library against EBV-VCA, and subsequently characterized these fragments by DNA sequencing and serial approaches.
We have identified the genes encoding the Fab-aVCA1 and Fab-aVCA21 antibodies. Both Fab fragments share the same V L chain, with homology to the closest germ line gene of 94%. The homologies of V H chain of Fab-aVCA1 and Fab-aVCA21 were 95 and 93%, respectively. In addition, we found that both Fab-aVCA21 and Fab-aVCA1 specifically bind to EBV-VCA in a concentration-dependent manner, as well as significantly reducing the binding of mouse mAb to EBV-VCA, suggesting that Fab-aVCA1 and Fab-aVCA21 bind to VCA epitopes with high affinity, similar to that of mouse mAb. By WB, we detected minor differences in the proteins bound by both Fab fragments and mouse mAb, suggesting that reactive epitopes may differ in EBV-infected humans and EBV-immunized mice (11) . Using IFA, we found that both Fab fragments could detect VCA protein in the EBV-positive P3HR1 cell line, which has been used for EBV serodiagnosis (30) , as well as in Daudi cell line. These findings strongly suggest that our two human Fabs can recognize EBV-VCA with high affinity. Finally, we confirmed the specificity of these two Fab fragments in tissues from five patients with EBV-positive lymphoid malignancies by immunohistochemistry and ISH. These results indicate that these two Fab fragments are novel human EBV-VCA specific mAbs. Altogether, these results help us to further understand the molecular profiles of human anti-EBV-VCA antibody and may provide the insight for future study leading to intracellular expression of antibodies (31) .
Hybridoma techniques to produce murine mAbs are quite expensive and require animal handling. In addition, the inherent immunogenicity of murine sequences in humans has presented obstacles to the clinical application of mouse mAbs. Human Fab should have reduced immunogenicity in humans, and may therefore have enhanced efficacy, safety and ease of use. In addition to phage display, transgenic mice can generate a full repertoire of human therapeutic mAbs and may facilitate the optimization of mAb production and open new therapeutic avenues (32, 33) . Although further studies are necessary to determine whether our two Fab fragments specific to EBV-VCA have protective activity in vitro and in vivo, these results may provide building blocks for the development of novel diagnostic and therapeutic approaches. . EBV-VCA detection with Fab-aVCA1 and Fab-aVCA21 by IHC and EBAR detection by ISH study. Deparaffinized slides were treated for 10 min with 3% H 2 O 2 . After antigen retrieval, the slides were incubated with 10 lg ml À1 Fabs for 1 h at RT. After extensive washing with PBS, the slides were incubated for 60 min at RT with HRP anti-human IgG F(ab') 2 for Fabs. The slides were stained with DAB substrate and counterstained with hematoxylin. Immunohistochemistry of EBV-positive LN tissues (A-E) and EBV-negative spleen tissues (F-J) with Fab-aVCA1 (B and G), Fab-aVCA21 (C and H), Fab anti-rotavirus (D and I), as well as ISH studies of EBV-positive (E) and negative (J) lymphoma tissues. (A) and (F) are stained with H&E.
